Abstract 913 Poster Session IV, Tuesday, 5/4 (poster 150)
Rotavirus is the leading cause of dehydrating gastrointestinal disease in infants and children. Most current vaccine strategies require multiple reassortant strains and 3 doses of vaccine for protection. In this study, we evaluated an attenuated human rotavirus G1 [P8] strain, 89-12 vaccine. A randomized placebo-controlled, double-blind trial of 215 infants was performed at 4 centers in the U.S. Infants 9-16 weeks of age received 2 oral doses of vaccine (105 pfu) or placebo and were followed by active surveillance through one rotavirus season. Side effects were minimal with a significant increase only in mild transient fever after the first dose (19% vs. 5%) but not G.I. symptoms. Irritability was significantly decreased in vaccine recipients (34 vs. 49%). Rotavirus antibody (IgA or 89-12 neutralizing) was induced in 94% of vaccine recipients vs. 4% of placebo recipients. Rotavirus disease was detected in 2 of 108 vaccine vs. 18 of 107 placebo recipients (p < .001, efficacy 89%, C.I. 65-97%). All ten infants requiring medical attention received placebo (p < .001 vaccine vs. placebo). The total number of rotavirus infections was also significantly decreased in vaccine recipients (18 vs. 30; p = .05). Further evaluations of this highly effective rotavirus vaccine are warranted. Funded by Avant Immunotherapeutics, Inc.
Dr. Bernstein is also a consultant for Avant Immunotherapeutics, Inc.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bernstein, D., Sack, D., Rothstein, E. et al. Efficacy of Live, Attenuated Human Rotavirus Vaccine (89-12) in Infants. Pediatr Res 45, 157 (1999). https://doi.org/10.1203/00006450-199904020-00930
Issue Date:
DOI: https://doi.org/10.1203/00006450-199904020-00930